Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
107,809,066
-
Total 13F shares
-
24,161,330
-
Share change
-
+6,733,813
-
Total reported value
-
$464,380,689
-
Put/Call ratio
-
75%
-
Price per share
-
$19.22
-
Number of holders
-
104
-
Value change
-
+$125,663,405
-
Number of buys
-
69
-
Number of sells
-
25
Institutional Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) as of Q4 2017
As of 31 Dec 2017,
Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) was held by
104 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
24,161,330 shares.
The largest 10 holders included
FMR LLC, Atlas Venture Associates IX, LLC, ORBIMED ADVISORS LLC, Vanguard Group Inc, BlackRock Inc., ARK Investment Management LLC, STATE STREET CORP, BAKER BROS. ADVISORS LP, FARALLON CAPITAL MANAGEMENT LLC, and Temasek Holdings (Private) Ltd.
This page lists
106
institutional shareholders reporting positions in this security
for the Q4 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.